ZAP‐70 Staining in Chronic Lymphocytic Leukemia

Neus Villamor1

1 Hospital Clínic de Barcelona, Barcelona, Spain
Publication Name:  Current Protocols in Cytometry
Unit Number:  Unit 6.19
DOI:  10.1002/0471142956.cy0619s32
Online Posting Date:  May, 2005
GO TO THE FULL TEXT: PDF or HTML at Wiley Online Library


Chronic lymphocytic leukemia (CLL) is the most common chronic leukemia in Western countries. The disease has an extremely variable clinical course, and several prognostic features have been identified to assess individual risk. The configuration of the immunoglobulin variable heavy‐chain gene (IgVH) is a strong predictor of the outcome. CLL patients with unmutated IgVH status have an aggressive clinical course and a short survival. Unfortunately, analysis of IgVH gene configuration is not available in most clinical laboratories. A small number of genes are differentially expressed between unmutated IgVH and mutated IgVH clinical forms of CLL. One of these genes is ZAP‐70, which is detected in leukemic cells from patients with the unmutated IgVH form of CLL. Flow cytometry presents advantages over other methods to detect ZAP‐70, and its quantification by flow cytometry has proved its predictive value. This unit focuses on protocols to quantify ZAP‐70 by flow cytometry in CLL.

Keywords: ZAP‐70; chronic lymphocytic leukemia; prognosis; B lymphocytes; mutational status of immunoglobulin variable heavy‐chain gene

PDF or HTML at Wiley Online Library

Table of Contents

  • Basic Protocol 1: Indirect Staining of Intracellular ZAP‐70
  • Alternate Protocol 1: Direct Immunofluorescence Staining of ZAP‐70
  • Commentary
  • Literature Cited
  • Figures
PDF or HTML at Wiley Online Library


Basic Protocol 1: Indirect Staining of Intracellular ZAP‐70

  • Whole peripheral blood sample, mononuclear cells, or thawed cryopreserved cells
  • Fixation and Permeabilization Kit formulated to study intracellular antigens in leukemia cells (Caltag, Dako)
  • Unconjugated MAb against ZAP‐70 (e.g., clone 2F3.2, available from Upstate Biotechnology, Novus Biological, LabVision, Diagnostic Biosystems, or Acris Antibodies GmbH; or clone 1E7.2, available from Caltag and Upstate Biotechnology), appropriately titered (unit 4.2)
  • Phosphate‐buffered saline (PBS; appendix 2A)
  • Fluorescein isothiocyanate (FITC)‐conjugated polyclonal goat anti‐mouse IgG F(ab′) 2, appropriately titered
  • Normal mouse serum
  • Fluorochrome‐conjugated MAbs against B lymphocytes (CD19‐PerCP‐Cy5.5), T&NK cells (PE‐conjugated, e.g., CD3 and CD56), and CLL cells (CD5‐APC), appropriately titered
  • 12 × 75–mm polystyrene tubes
  • Flow cytometer with a 488‐nm HeNe laser and a 635‐nm red diode laser

Alternate Protocol 1: Direct Immunofluorescence Staining of ZAP‐70

  • Fluorochrome‐conjugated MAb against ZAP‐70 conjugated to Alexa Fluor 488 (Caltag), isotypic MAb conjugated to Alexa Fluor 488, MAb against B lymphocytes (CD19‐PerCP‐Cy5.5), MAb against T&NK cells (PE‐conjugated, e.g., CD3 and CD56), and MAb against CLL cells (CD5‐APC), appropriately titered
PDF or HTML at Wiley Online Library



Literature Cited

Literature Cited
   Byrd, J.C., Stilgenbauer, S., and Flinn, I.W. 2004. Chronic lymphocytic leukemia. Hematology (Am. Soc. Hematol. Educ. Program) 2004:163‐183.
   Carreras, J., Villamor, N., Colomo, L., Moreno, C., Ramon y Cajal, S., Crespo, M., Tort, F., Bosch, F., Lopez‐Guillermo, A., Colomer, D., Montserrat, E., and Campo, E. 2005. ZAP‐70 expression in B‐cell lymphoid neoplasms: An immunohistochemical study. J. Pathol. 205:507‐513.
   Chen, L., Widhopf, G., Huynh, L., Rassenti, L., Rai, K.R., Weiss, A., and Kipps, T.J. 2002. Expression of ZAP‐70 is associated with increased B‐cell receptor signaling in chronic lymphocytic leukemia. Blood 100:4609‐4614.
   Chen, L., Apgar, J., Huynh, L., Dicker, F., Giago‐McGahan, T., Rassenti, L., Weiss, A., and Kipps, T.J. 2004. ZAP‐70 directly enhances IgM signaling in chronic lymphocytic leukemia. Blood 105:2036‐2041.
   Crespo, M., Bosch, F., Villamor, N., Bellosillo, B., Colomer, D., Rozman, M., Marce, S., Lopez‐Guillermo, A., Campo, E., and Montserrat, E. 2003. ZAP‐70 expression as a surrogate for immunoglobulin‐variable‐region mutations in chronic lymphocytic leukemia. N. Engl. J. Med. 348:1764‐1775.
   Damle, R.N., Wasil, T., Fais, F., Ghiotto, F., Valetto, A., Allen, S.L., Buchbinder, A., Budman, D., Dittmar, K., Kolitz, J., Lichtman, S.M., Schulman, P., Vinciguerra, V.P., Rai, K.R., Ferrarini, M., and Chiorazzi, N. 1999. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 94:1840‐1847.
   Durig, J., Nuckel, H., Cremer, M., Fuhrer, A., Halfmeyer, K., Fandrey, J., Moroy, T., Klein‐Hitpass, L., and Duhrsen, U. 2003. ZAP‐70 expression is a prognostic factor in chronic lymphocytic leukemia. Leukemia 17:2426‐2434.
   Hamblin, T.J., Davis, Z., Gardiner, A., Oscier, D.G., and Stevenson, F.K. 1999. Unmutated Ig VH genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 94:1848‐1854.
   Montserrat, E. 2002. Classical and new prognostic factors in chronic lymphocytic leukemia: Where to now? Hematol. J. 3:7‐9.
   Müller‐Hermelink, H.K., Montserrat, E., Catovsky, D., and Harris, N.L. 2001. Chronic lymphocytic leukaemia/small lymphocytic lymphoma. In World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues (E.S. Jaffe, N.L. Harris, H. Stein, and J.W. Vardiman, eds.) pp. 127‐130. IARC Press, Lyon.
   Orchard, J.A., Ibbotson, R.E., Davis, Z., Wiestner, A., Rosenwald, A., Thomas, P.W., Hamblin, T.J., Staudt, L.M., and Oscier, D.G. 2004. ZAP‐70 expression and prognosis in chronic lymphocytic leukaemia. Lancet 363:105‐111.
   Rassenti, L.Z., Huynh, L., Toy, T.L., Chen, L., Keating, M.J., Gribben, J.G., Neuberg, D.S., Flinn, I.W., Rai, K.R., Byrd, J.C., Kay, N.E., Greaves, A., Weiss, A., and Kipps, T.J. 2004. ZAP‐70 compared with immunoglobulin heavy‐chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N. Engl. J. Med. 351:893‐901.
   Rosenwald, A., Alizadeh, A.A., Widhopf, G., Simon, R., Davis, R.E., Yu, X., Yang, L., Pickeral, O.K., Rassenti, L.Z., Powell, J., Botstein, D., Byrd, J.C., Grever, M.R., Cheson, B.D., Chiorazzi, N., Wilson, W.H., Kipps, T.J., Brown, P.O., and Staudt, L.M. 2001. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J. Exp. Med. 194:1639‐1647.
   Rozman, C. and Montserrat, E. 1995. Chronic lymphocytic leukemia. N. Engl. J. Med. 333:1052‐1057.
   Wiestner, A., Rosenwald, A., Barry, T.S., Wright, G., Davis, R.E., Henrickson, S.E., Zhao, H., Ibbotson, R.E., Orchard, J.A., Davis, Z., Stetler‐Stevenson, M., Raffeld, M., Arthur, D.C., Marti, G.E., Wilson, W.H., Hamblin, T.J., Oscier, D.G., and Staudt, L.M. 2003. ZAP‐70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood 101:4944‐4951.
PDF or HTML at Wiley Online Library